On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: Effectiveness, health-related quality of life, and patient satisfaction

Digestive Diseases and Sciences

Volumn 49, Issue 6, 2004, Pages 931-936

  Ponce, Julio ^a   Argüello, Lidia ^a   Bastida, Guillermo ^a   Ponce, Marta ^a   Ortiz, Vicente ^a   Garrigues, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

gastroesophageal reflux disease; on demand therapy; proton pump inhibitors; quality of life

Indexed keywords

PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HEALING; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REFLUX ESOPHAGITIS; SYMPTOMATOLOGY; VISUAL ANALOG SCALE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; ESOPHAGITIS; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 3543002869     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000034551.39324.c3     Document Type: Article

References (33)

1. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: A systematic review. Scand J Gastroenterol 231 (Suppl):3-8, 1999
2. Johanson JF: Epidemiology of esophageal and supraesophageal reflux injuries. Am J Med 108 (Suppl 4A):99S-103S, 2000
3. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gasfroesophageal reflux disease on health-related quality of life. Am J Med 104:252-258, 1998
4. Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberod A, Anker-Hansen O: Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole. Am J Gastroenterol 94:1782-1789, 1999
5. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119:654-660, 2000
6. Eloubeidi MA, Provenzale D: Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 95:1881-1887, 2000
7. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 112:1798-1810, 1997
8. van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inihibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). The Cochrane Library, Issue 2, Oxford, Update Software, 2000
9. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA: Three year follow-up of patients with gastroesophageal reflux disease. Gut 33:1016-1019, 1992
10. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10:119-124, 1998
11. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ: An evidence-based appraisal of reflux disease management - The Genval Workshop report. Gut 44 (Suppl 2): S1-S16, 1999
12. Bardhan KD, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir DG, Gillon KR, Peacock RA, Fulton C: Symptomatic gastro-oesophageal reflux disease: Double blind controlled study of intermittent treatment with omprazole or ranitidine. Br Med J 318:502-507, 1999
13. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghard O: On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial. Aliment Pharmacol Ther 13:907-914, 1999
14. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of "on-demand" therapy for 6 months. Aliment Pharmacol Ther 15:347-354, 2001
15. Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer M, Bardhan KD, Carlsson RG, Chen S, Hasselgren GS: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 14:857-863, 2002
16. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: The endocopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 111:85-92, 1996
17. Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483, 1992
18. Alonso J, Prieto L, Anto JM: The Spanish version of the SF-36 health survey (the SF-36 health questionnaire): An instrument for measuring clinical results. Med Clin (Barc) 104:771-776, 1995
19. Alonso J, Regidor E, Barrio G, Prieto L, Rodriguez C, De la Fuente L: Population reference values of the Spanish version of the Health Questionnaire SF-36. Med Clin (Barc) 111:410-416, 1998
20. Compte L, Garrigues V, Perpiñá M, Ponce J: Prevalence of gastroesophageal reflux in asthma. J Asthma 37:175-182, 2000
21. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G: A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 95:395-407, 2000
22. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13:49-57, 1999
23. Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S: Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 97:1332-1339, 2002
24. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L: Onset of symptom relief with rabeprazole: A community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16:445-454, 2002
25. Dent J, Talley NJ: Overview: Initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 17(Suppl 1):53-57, 2003
26. Bytzer P: On-demand therapy for gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 13(Suppl 1):S19-S22, 2001
27. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-hour intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079-1089, 1998
28. Heading RC: Long-term management of gastro oesophageal reflux disease. Scand J Gastroenterol 30(Suppl 213):25-30, 1995
29. Hungin AP, Rubin G, O'Flanagan H: Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 49:463-464, 1999
30. Johanson JF, Siddique R, Damiano AM, Jokubaitis L, Murthy A, Bhattacharjya A: Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci 47:2574-2578, 2002
31. Stalhammar NO, Carlsson J, Peacock R, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir DG, Fulton C, Gillon K, Bardhan KD: Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-esophageal reflux disease. Pharmacoeconomics 16:483-497, 1999
32. Wahlqvist P, Junghard O, Higgins A, Green J: Cost-effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 20:267-277, 2002
33. Inadomi JM: On-demand and intermittent therapy for gastro-oesophageal reflux disease: Economic considerations. Pharmacoeconomics 20:565-576, 2002